Proposal for the administration of metformin in patients with chronic kidney disease;Javaslat a metformin idült vesebetegségben történo alkalmazásának módosítására

Orvosi Hetilap

Volumn 153, Issue 39, 2012, Pages 1527-1535

  Balogh, Zoltán ^a   Mátyus, János ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

cardiovascular effects; chronic kidney disease; lactic acidosis; metformin

Indexed keywords

INSULIN DERIVATIVE; METFORMIN;

ACUTE KIDNEY FAILURE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HUMAN; HYPOVOLEMIA; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER FAILURE; SEPSIS;

ACIDOSIS, LACTIC; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84866852881     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2012.29448     Document Type: Article

References (52)

1. UKPDS Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. United Kingdom Prospective Diabetes Study. Lancet, 1998, 352, 854-855.
2. Holman, R. R., Paul, S. K., Bethel, M. A., et al.: 10-year followup of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 2008, 359, 1577-1589.
3. Kooy, A., de Jager, J., Lehert, P., et al.: Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med., 2009, 169, 616-625.
4. Johnson, J. A., Majumdar, S. R., Simpson, S. H., et al.: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care, 2002, 25, 2244-2248.
5. Sherifali, D., Nerenberg, K., Pullenayegum, E., et al.: The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care, 2010, 33, 1859-1864.
6. Pilmore, H. L.: Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton), 2010, 15, 412-418.
7. Klachko, D., Whaley-Connell, A.: Use of metformin in patients with kidney and cardiovascular diseases. Cardiorenal. Med., 2011, 1, 87-95.
8. Bailey, C. J., Turner, R. C.: Metformin. N. Engl. J. Med., 1996, 334, 574-579.
9. Libby, G., Donnelly, L. A., Donnan, P. T., et al.: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 2009, 32, 1620-1625.
10. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., et al.: Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005, 328, 1304-1305.
11. Dowling, R. J., Niraula, S., Stambolic, V., et al.: Metformin in cancer: translational challenges. J. Mol. Endocrinol., 2012, 48, R31-R43.
12. Douek, I. F., Allen, S. E., Ewings, P., et al., for the Metformin Trial Group: Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet. Med., 2005, 22, 634-640.
13. Ismail-Beigi, F., Moghissi, E., Tiktin, M., et al.: Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann. Intern. Med., 2011, 154, 554-559.
14. ACCORD Study Group, Gerstein, H. C., Miller, M. E., Genuth, S., et al.: Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med., 2011, 364, 818-828.
15. Nathan, D. M., Buse, J. B., Davidson, M. B., et al.: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009, 32, 193-203.
16. National Institute for Health and Clinical Excellence: Type 2 diabetes: The management of type 2 diabetes. (Clinical guideline 87.) NICE, London, 2008. www.nice.org.uk/CG87
17. Diagnosis, treatment and care of diabetes in adulthood. Clinical Practice Recommendations of the Hungarian Diabetes Association-2011. [A diabetes mellitus kórismézése, a cukorbetegek kezelése és gondozaása feln?ttkorban. A Magyar Diabetes Taársasaág szakmai iraányelve-2011.] (Ed.: Jermendy, Gy.). Diabetol. Hung., 2011, 19 (Suppl. 1), 5-72. [Hungarian]
18. McCormack, J., Johns, K., Tildesley, H.: Metformin's contraindications should be contraindicated. CMAJ, 2005, 173, 502-504.
19. Senior, P. A.: Type 2 diabetes, metformin and lactic acidosisdefi ning the risk and promoting safe practice (editorial). Diabet. Med., 2012, 29, 161-163.
20. Scale, T., Harvey, J. N.: Diabetes, metformin and lactic acidosis. Clin. Endocrinol. (Oxf.), 2011, 74, 191-196.
21. Pongwecharak, J., Tengmeesri, N., Malanusorn, N., et al.: Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm. World Sci., 2009, 31, 481-486.
22. Holstein, A., Nahrwold, D., Hinze, S., et al.: Contra-indications to metformin therapy are largely disregarded. Diabet. Med., 1999, 16, 692-696.
23. Lipska, K. J., Bailey, C. J., Inzucchi, S. E.: Use of metformin in the setting of mild to moderate renal insuffi ciency. Diabetes Care, 2011, 34, 1431-1437.
24. Levin, A., Hemmelgarn, B., Culleton, B., et al.: Guidelines for the management of chronic kidney disease. CMAJ, 2008, 179, 1154-1162.
25. Colagiuri, S., Dickenson, S., Girgis, S., et al.: National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Diabetes Australia and the NHMRC, Canberra, 2009.
26. Maátyus, J., V. Olaáh, A., Ujhelyi, L., et al.: The epidemic of chronic kidney disease requires the estimation of glomerular fi ltration rate. [Az idült vesebetegség epidémiaája szükségessé teszi a glomerulusfi ltraációs raáta szaámítaásaát.] Orv. Hetil., 2008, 149, 78-82. [Hungarian]
27. Hamilton, C. A.: Pharmacological management of type 2 diabetes mellitus in patients with CKD. J. Ren. Care, 2012, 38 (Suppl. 1), 59-66.
28. Kis, J. T.: The newest DPP-4-inhibitor: linagliptin. [A legújabb DPP-4-gaátló: a linagliptin.] LAM, 2011, 21, 773-777. [Hungarian]
29. Tzvetkov, M. V., Vormfelde, S. V., Balen, D., et al.: The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther., 2009, 86, 299-306.
30. Graham, G. G., Punt, J., Arora, M., et al.: Clinical pharmacokinetics of metformin. Clin. Pharmacokinet., 2011, 50, 81-98.
31. Frid, A., Sterner, G. N., Löndahl, M., et al.: Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care, 2010, 33, 1291-1293.
32. Ellis, A. K., Iliescu, E. A.: Metformin-associated lactic acidosis in a low risk patient. Can. J. Clin. Pharmacol., 2001, 8, 104-106.
33. Lalau, J. D., Lacroix, C., Compagnon, P., et al.: Role of metformin accumulation in metformin associated lactic acidosis. Diabetes Care, 1995, 18, 779-784.
34. Lalau, J. D., Race, J. M.: Lactic acidosis in metformin therapy: searching for a link with metformin in reports of "metforminassociated lactic acidosis". Diabetes Obes. Metab., 2001, 3, 195-201.
35. Luft, F. C.: Lactic acidosis update for critical care clinicians. J. Am. Soc. Nephrol., 2001, 12 (Suppl. 17), S15-S19.
36. Finkle, S. N.: Should dialysis be offered in all cases of metforminassociated lactic acidosis? Crit. Care, 2009, 13, 110-111.
37. Seidowsky, A., Nseir, S., Houdret, N., et al.: Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit. Care Med., 2009, 37, 2191-2196.
38. Balogh, Z., Paragh, Gy.: Diabetic metabolic emergencies. [Akut anyagcsere-krízisek diabetes mellitusban]. Orv. Hetil., 2005, 146, 443-450. [Hungarian]
39. Salpeter, S. R., Greyber, E., Pasternak, G. A., et al.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev., 2010, 4, CD002967.
40. Bodmer, M., Meier, C., Krahenbuhl, S., et al.: Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care, 2008, 31, 2086-2091.
41. Nye, H. J., Herrington, W. G.: Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron. Clin. Pract., 2011, 118, c380-c383.
42. Salpeter, S. R., Greyber, E., Pasternak, G. A., et al.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch. Intern. Med., 2003, 163, 2594-2602.
43. Campbell, I. W.: Metformin and the sulphonylureas: the comparative risk. Horm. Metab. Res. Suppl., 1985, 15, 105-111.
44. Nisbet, J. C., Sturtevant, J. M., Prins, J. B.: Metformin and serious adverse effects. Med. J. Aust., 2004, 180, 53-54.
45. Balogh, Z., Sira, L., Köbling, T., et al.: Bilateral renal papillary necrosis and lactic acidosis in patient with type 2 diabetes mellitus. [Kétoldali vesepapilla nekrózis és laktaátacidosis 2-es típusú diabetes mellitusban.] Metabolizmus, 2003, 1, 208-211. [Hungarian]
46. Emslie-Smith, A. M., Boyle, D. I. R., Evans, J. M. M., et al.: Contraindications to metformin therapy in patients with type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet. Med., 2001, 18, 483-488.
47. Weekes, A. J., Thomas, M. C.: The use of oral antidiabetic agents in primary care. Aust. Fam. Physician, 2007, 36, 477-479.
48. Vasisht, K. P., Chen, S. C., Peng, Y., et al.: Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes. Metab., 2010, 12, 1079-1083.
49. Warren, R. E., Strachan, M. W., Wild, S., et al.: Introducing estimated glomerular fi ltration rate (eGFR) into clinical practice in the UK: implications for the use of metformin. Diabet. Med., 2007, 24, 494-497
50. Roussel, R., Travert, F., Pasquet, B., et al.: Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med., 2010, 170, 1892-1899.
51. Jones, G. R.: Estimating renal function for drug dosing decisions. Clin. Biochem. Rev., 2011, 32, 81-88.
52. Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al.: Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2012, 35, 1364-1379.